Horizon / Plein textes La base de ressources documentaires de l'IRD

IRD

 

Publications des scientifiques de l'IRD

Thiam M., Diop-Ndiaye H., Diouf A. D., Vidal Nicole, Ndiaye O., Ndiaye I., Ngom-Gueye N. F., Diallo S., Diongue O. D., Camara M., Seck A., Mboup S., Toure-Kane C. (2013). HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system. Journal of Clinical Microbiology, 51 (2), 578-584. ISSN 0095-1137

Lien direct chez l'éditeur doi:10.1128/jcm.02452-12

Titre
HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system
Année de publication2013
Type de documentArticle référencé dans le Web of Science WOS:000314108000028
AuteursThiam M., Diop-Ndiaye H., Diouf A. D., Vidal Nicole, Ndiaye O., Ndiaye I., Ngom-Gueye N. F., Diallo S., Diongue O. D., Camara M., Seck A., Mboup S., Toure-Kane C.
SourceJournal of Clinical Microbiology, 2013, 51 (2), p. 578-584. ISSN 0095-1137
RésuméIn this study, we investigated the prevalence of human immunodeficiency virus type 1 (HIV-1) drug resistance mutations and genetic variability among Senegalese patients undergoing highly active antiretroviral therapy (ART) in the public health system. We conducted a cross-sectional study of 72 patients with suspected therapeutic failure. HIV-1 genotyping was performed with Viroseq HIV-1 Genotyping System v2.0 or the procedure developed by the ANRS AC11 resistance study group, and a phylogenetic analysis was performed. The median follow-up visit was at 40 (range, 12 to 123) months, and the median viral load was 4.67 (range, 3.13 to 6.94) log(10) copies/ml. The first-line therapeutic regimen was nucleoside reverse transcriptase inhibitors (NRTIs) plus efavirenz (EFV) or NRTIs plus nevirapine (NVP) (54/72 patients; 75%), and the second-line therapy was NRTIs plus a protease inhibitor (PI/r) (18/72; 25%). Fifty-five patients (55/72; 76.39%) had at least one drug resistance mutation. The drug resistance rates were 72.22 and 88.89% for the first-line and second-line ARTs, respectively. In NRTI mutations, thymidine analog mutations (TAMs) were found in 50.79% and the M184V mutation was found in 34.92% of the samples. For non-NRTI resistance, we noted a predominance of the K103N mutation (46.27%). For PI/r, several cases of mutations were found with a predominance of M46I and L76V/F at 24% each. The phylogenetic analysis revealed CRF02_AG as the predominant circulating recombinant form (43/72; 59.72%). We found a high prevalence of resistance mutations and a high rate of TAMs among Senegalese patients in the public health system. These findings emphasize the need to improve virological monitoring in resource-limited settings.
Plan de classementEntomologie médicale / Parasitologie / Virologie [052] ; Santé : généralités [050]
Descr. géo.SENEGAL
LocalisationFonds IRD
Identifiant IRDPAR00010187
Lien permanenthttp://www.documentation.ird.fr/hor/PAR00010187

Export des données

Disponibilité des documents

Télechargment fichier PDF téléchargeable

Lien sur le Web lien chez l'éditeur

Accès réservé en accès réservé

HAL en libre accès sur HAL


Accès aux documents originaux :

Le FDI est labellisé CollEx

Accès direct

Bureau du chercheur

Site de la documentation

Espace intranet IST (accès réservé)

Suivi des publications IRD (accès réservé)

Mentions légales

Services Horizon

Poser une question

Consulter l'aide en ligne

Déposer une publication (accès réservé)

S'abonner au flux RSS

Voir les tableaux chronologiques et thématiques

Centres de documentation

Bondy

Montpellier (centre IRD)

Montpellier (MSE)

Cayenne

Nouméa

Papeete

Abidjan

Dakar

Niamey

Ouagadougou

Tunis

La Paz

Quito